Arctigenin treatment significantly decreased the blood levels of leptin, tumor necrosis factor (TNF)-α, IGF-1, interleukin (IL)-6, VEGF, IL-1a, IL-1b, and MCP-1 by 30–35% compared to HF control (Fig. 4C). This evidence concerns the gene IL1B and hydrops fetalis.